Differentiated Thyroid Cancer with a Focus on Adverse Event Management

In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

Lova Sun, MD, MCSE, discussed genetic mutations in thyroid cancer and how they impact clinicians’ treatment options.

Lori J. Wirth, MD, discussed advancements in diagnosing and treating thyroid cancer, offering community oncologists improved tools for identifying low-risk cancers, personalizing treatment, and exploring innovative approaches.

Whole-exome sequencing identified genetic mutations associated with poorly differentiated thyroid cancer, paving a new path for research in the field.

Health-related, mental, and emotional quality of life often suffer when patients with thyroid cancer undergo thyroidectomy. However, research shows it may be only in the short-term.